原发性脑肿瘤放疗后永久性脱发:影响最大的因素

Simin Badiei Moghaddam, Afshin Rakhsha, Zahra Siavashpour
{"title":"原发性脑肿瘤放疗后永久性脱发:影响最大的因素","authors":"Simin Badiei Moghaddam, Afshin Rakhsha, Zahra Siavashpour","doi":"10.1016/j.canrad.2024.05.003","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Alopecia is a distressing side effect of radiotherapy in patients undergoing treatment for primary brain tumours. This study aimed to investigate the most influential clinical, demographic, and dosimetric factors associated with permanent scalp alopecia in patients with brain tumours treated with intensity-modulated radiations.</p><p><strong>Patients and methods: </strong>Eighty patients with brain tumors treated with intensity-modulated radiations were enrolled. Inclusion criteria were having a primary brain tumour and patients with at least 18 months of radiotherapy. Scalp alopecia was evaluated using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. The scalp location with hair loss was marked and delineated on their follow-up MRI, and the planning dosimetric parameters, including D<sub>0.1cm</sub><sup>3</sup> (as maximum dose), mean dose, and various volumetric parameters such as V<sub>16Gy-43Gy</sub> (with about 5Gy interval) were recorded. In addition, receiver operating characteristic (ROC) curve analysis was employed to identify predictive parameters for chronic alopecia.</p><p><strong>Results: </strong>The hair loss severity was grade 1 for 70 % of cases, and grade 2 for 30 %. Male gender, history of chemotherapy, and family history of hair loss were significantly associated with increased volume of hair loss follicles. The correlation and ROC analysis revealed that regions receiving doses of 30Gy or higher (i.e., V<sub>30Gy</sub>) were associated with a higher risk of developing grade 2 alopecia. The resulting areas under the curve of 0.694 were indicators for moderate correlations between the considered dose-volume histogram parameters and patients' permanent alopecia. Even if these results were not statistically significant, these findings suggest that specific dosimetric parameters, such as V<sub>30Gy</sub> to V<sub>43Gy</sub>, maybe the strongest predictors of grade 2 chronic radiation-induced alopecia. The cut-off values were also about 13.5 to 8 cm<sup>3</sup> for V<sub>30Gy</sub> to V<sub>43Gy</sub>, respectively, which can be played as an indicator of the dose-volume histogram threshold above which permanent alopecia will be expected after brain intensity-modulated radiotherapy.</p><p><strong>Conclusion: </strong>The incidence of permanent alopecia after intensity-modulated radiotherapy is influenced by demographic, dosimetric, and clinical factors such as gender, history of chemotherapy, and family history, and the skull follicle regions receiving doses of 30Gy or higher.</p>","PeriodicalId":93921,"journal":{"name":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Permanent alopecia after radiotherapy of primary brain tumours: The most influential factors.\",\"authors\":\"Simin Badiei Moghaddam, Afshin Rakhsha, Zahra Siavashpour\",\"doi\":\"10.1016/j.canrad.2024.05.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Alopecia is a distressing side effect of radiotherapy in patients undergoing treatment for primary brain tumours. This study aimed to investigate the most influential clinical, demographic, and dosimetric factors associated with permanent scalp alopecia in patients with brain tumours treated with intensity-modulated radiations.</p><p><strong>Patients and methods: </strong>Eighty patients with brain tumors treated with intensity-modulated radiations were enrolled. Inclusion criteria were having a primary brain tumour and patients with at least 18 months of radiotherapy. Scalp alopecia was evaluated using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. The scalp location with hair loss was marked and delineated on their follow-up MRI, and the planning dosimetric parameters, including D<sub>0.1cm</sub><sup>3</sup> (as maximum dose), mean dose, and various volumetric parameters such as V<sub>16Gy-43Gy</sub> (with about 5Gy interval) were recorded. In addition, receiver operating characteristic (ROC) curve analysis was employed to identify predictive parameters for chronic alopecia.</p><p><strong>Results: </strong>The hair loss severity was grade 1 for 70 % of cases, and grade 2 for 30 %. Male gender, history of chemotherapy, and family history of hair loss were significantly associated with increased volume of hair loss follicles. The correlation and ROC analysis revealed that regions receiving doses of 30Gy or higher (i.e., V<sub>30Gy</sub>) were associated with a higher risk of developing grade 2 alopecia. The resulting areas under the curve of 0.694 were indicators for moderate correlations between the considered dose-volume histogram parameters and patients' permanent alopecia. Even if these results were not statistically significant, these findings suggest that specific dosimetric parameters, such as V<sub>30Gy</sub> to V<sub>43Gy</sub>, maybe the strongest predictors of grade 2 chronic radiation-induced alopecia. The cut-off values were also about 13.5 to 8 cm<sup>3</sup> for V<sub>30Gy</sub> to V<sub>43Gy</sub>, respectively, which can be played as an indicator of the dose-volume histogram threshold above which permanent alopecia will be expected after brain intensity-modulated radiotherapy.</p><p><strong>Conclusion: </strong>The incidence of permanent alopecia after intensity-modulated radiotherapy is influenced by demographic, dosimetric, and clinical factors such as gender, history of chemotherapy, and family history, and the skull follicle regions receiving doses of 30Gy or higher.</p>\",\"PeriodicalId\":93921,\"journal\":{\"name\":\"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-11-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.canrad.2024.05.003\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.canrad.2024.05.003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的:脱发是原发性脑肿瘤患者接受放疗时出现的一种令人痛苦的副作用。本研究旨在调查与接受调强放射治疗的脑肿瘤患者永久性头皮脱发相关的最有影响力的临床、人口统计学和剂量学因素:共招募了80名接受调强放射治疗的脑肿瘤患者。纳入标准为患有原发性脑肿瘤且接受过至少 18 个月的放疗。头皮脱发采用不良事件通用术语标准(CTCAE)v5.0进行评估。在随访的磁共振成像上标记和划定脱发的头皮位置,并记录计划剂量参数,包括D0.1cm3(最大剂量)、平均剂量和各种体积参数,如V16Gy-43Gy(间隔约5Gy)。此外,还采用了接收器操作特征(ROC)曲线分析来确定慢性脱发的预测参数:结果:70%的病例脱发严重程度为一级,30%为二级。男性性别、化疗史和脱发家族史与脱发毛囊数量增加有显著相关性。相关性和 ROC 分析表明,接受 30Gy 或更高剂量(即 V30Gy)治疗的区域出现 2 级脱发的风险较高。由此得出的曲线下面积为 0.694,表明所考虑的剂量-体积直方图参数与患者永久性脱发之间存在中度相关性。尽管这些结果在统计学上并不显著,但这些研究结果表明,特定的剂量学参数,如 V30Gy 至 V43Gy,可能是预测 2 级慢性放射诱导性脱发的最有力指标。V30Gy至V43Gy的临界值也分别约为13.5至8立方厘米,这可以作为脑部调强放疗后剂量-体积直方图阈值的指标,超过该阈值将出现永久性脱发:结论:调强放疗后永久性脱发的发生率受人口统计学、剂量学和临床因素(如性别、化疗史和家族史)以及接受30Gy或更高剂量的颅骨滤泡区的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Permanent alopecia after radiotherapy of primary brain tumours: The most influential factors.

Purpose: Alopecia is a distressing side effect of radiotherapy in patients undergoing treatment for primary brain tumours. This study aimed to investigate the most influential clinical, demographic, and dosimetric factors associated with permanent scalp alopecia in patients with brain tumours treated with intensity-modulated radiations.

Patients and methods: Eighty patients with brain tumors treated with intensity-modulated radiations were enrolled. Inclusion criteria were having a primary brain tumour and patients with at least 18 months of radiotherapy. Scalp alopecia was evaluated using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. The scalp location with hair loss was marked and delineated on their follow-up MRI, and the planning dosimetric parameters, including D0.1cm3 (as maximum dose), mean dose, and various volumetric parameters such as V16Gy-43Gy (with about 5Gy interval) were recorded. In addition, receiver operating characteristic (ROC) curve analysis was employed to identify predictive parameters for chronic alopecia.

Results: The hair loss severity was grade 1 for 70 % of cases, and grade 2 for 30 %. Male gender, history of chemotherapy, and family history of hair loss were significantly associated with increased volume of hair loss follicles. The correlation and ROC analysis revealed that regions receiving doses of 30Gy or higher (i.e., V30Gy) were associated with a higher risk of developing grade 2 alopecia. The resulting areas under the curve of 0.694 were indicators for moderate correlations between the considered dose-volume histogram parameters and patients' permanent alopecia. Even if these results were not statistically significant, these findings suggest that specific dosimetric parameters, such as V30Gy to V43Gy, maybe the strongest predictors of grade 2 chronic radiation-induced alopecia. The cut-off values were also about 13.5 to 8 cm3 for V30Gy to V43Gy, respectively, which can be played as an indicator of the dose-volume histogram threshold above which permanent alopecia will be expected after brain intensity-modulated radiotherapy.

Conclusion: The incidence of permanent alopecia after intensity-modulated radiotherapy is influenced by demographic, dosimetric, and clinical factors such as gender, history of chemotherapy, and family history, and the skull follicle regions receiving doses of 30Gy or higher.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Is hypofractionated radiotherapy used to treat soft tissue sarcomas? Assessment of practices using the NETSARC network. Management of unilateral neck irradiation in elderly patients with head and neck cancer: Which place for hypofractionation? A single-centre experience of 43 patients. Oncological outcomes of patients with muscle-invasive bladder cancer treated with trimodal strategy: A French multicentric study. Permanent alopecia after radiotherapy of primary brain tumours: The most influential factors. Safety of concurrent trastuzumab-emtansine and radiation therapy for breast cancer: Single-centre experience from a morbidity and mortality review meetings procedure.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1